Champions Oncology Q2 revenue up 11% to $15M; net income $237K, adj EBITDA $843K; positive outlook

CHAMPIONS ONCOLOGY, INC.

2026-Q2 EPS reported -$0.01 revenue$29,030,000

Q2 total revenue $15.0M (+11% YoY); oncology services profit $7.8M, margin 52% vs 45%.
Net income $237K; adjusted EBITDA $843K; prior-year net income $728K, adj. EBITDA $1.1M.
Year-to-date revenue $29.0M (+5%); net loss $230K; adj. EBITDA $962K vs $3.2M prior.
Cash $8.5M, no debt; management on track for full-year revenue growth and positive adj. EBITDA.
R&D spend up 55% YoY, G&A up 57% on investments in data platform and business development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.